| Cat. No. |
Product Name |
Information |
| PC-42036 |
LY3177833
CDC7 inhibitor
|
LY3177833 is a potent and selective CDC7 inhibitor with IC50 of 3.3 nM. |
| PC-42060 |
AZD-5438
CDK1/2/9 inhibitor
|
AZD-5438 (AZD5438) potent and oral inhibitor of CDK1/2/9 with IC50 of 16/6/20 nM, respectively. |
| PC-42425 |
Senexin B
CDK8/CDK19 inhibitor
|
Senexin B (SNX2-1-165) is a highly potent, selective and orally available CDK8/CDK19 inhibitor with IC50 of 24-50 nM. |
| PC-42527 |
JNJ-7706621
CDK/Aurora inhibitor
|
JNJ-7706621 is a potent, dual CDK/Aurora kinase inhibitor with IC50 of 9/4/11/15 nM for CDK1/CDK2/Aurora A/Aurora B respectively. |
| PC-24960 |
Mocaciclib
CDK7 inhibitor
|
Mocaciclib (Q901) is a highly selective and potent CDK7 inhibitor, forms a covalent bond with C312 of the CDK7 C-terminal domain. |
| PC-24915 |
AS3334366
CDK8/19 inhibitor, Foxp3 inducer
|
AS3334366 is a potent, selective orally active inhibitor of CDK8 and CDK19 with IC50 of 0.68 nM and 1.9 nM, respectively, AS2863619 is a potent Foxp3 inducer in Tconv cells with EC50 of 13.1 nM. |
| PC-24914 |
AS2863619
CDK8/19 inhibitor, Foxp3 inducer
|
AS2863619 is a potent, selective and orally active inhibitor of CDK8 and CDK19 with IC50 of 0.61 nM and 4.28 nM, respectively, AS2863619 is a potent Foxp3 inducer in Tconv cells with EC50 of 32.5 nM. |
| PC-24695 |
FCN-437c
CDK4/6 inhibitor
|
FCN-437c (FCN-437) is a potent, selective and orally active inhibitor of CDK4/6, shows selective inhibitory activities against CDK4/6 over other CDKs. |
| PC-24657 |
Bireociclib
CDK4/6 inhibitor
|
Bireociclib (XZP-3287) is a novel potent, selective cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor with IC50 of 2.7/16 nM respectively. |
| PC-24595 |
MRT-9643
CDK2 degrader
|
MRT-9643 (MRT9643) is a potent, selective and orally active CDK2-directed molecular glue degrader, induces CDK2-dependent cancer cell growth inhibition. |
| PC-24494 |
Y041-2712
CDK8 inhibitor
|
Y041-2712 is a potent, selective CDK8 inhibitor with IC50 value of 398.8 nM, inhibits TGF-β/Smad signaling pathway and the expression of EMT proteins. |
| PC-24482 |
LA-CB1
CDK4/6 degrader
|
LA-CB1 is a novel Abemaciclib derivative that induces CDK4/6 degradation through the ubiquitin-proteasome pathway, exerts robust anti-proliferative effects across a wide spectrum of cancer cell lines (A498 cell, IC50=0.21 uM). |
